Potential role of selected biomarkers for predicting the presence and extent of coronary artery disease

Biomedical Papers

Volumn 154, Issue 3, 2010, Pages 219-226

  Griva, Martin ^a   Naplava, Robert ^a   Spendlikova, Milada ^a   Jarkovsky, Jiri ^b   Hlinomaz, Ota ^c   Cihalik, Cestmir ^a  

^a T Bata's Regional Hospital   (Czech Republic)

^b MASARYK UNIVERSITY   (Czech Republic)

^c ST ANNE S UNIVERSITY HOSPITAL   (Czech Republic)

Author keywords

Coronary artery disease; Macrophage chemoattractant protein 1; Matrix metalloproteinase 3; Soluble cd40 ligand; Soluble tumour necrosis factor receptor 2; Syntax score

Indexed keywords

EID: 78049298212     PISSN: 12138118     EISSN: 12138118     Source Type: Journal    
DOI: 10.5507/bp.2010.033     Document Type: Article

References (36)

1. European detailed mortality database (DMDB). Copenhagen, WHO Regional Office for Europe, 2010.
2. Bastarrika G, Lee YS, Huda W, Ruzsics B, Costello P, Schoepf UJ. CT of coronary artery disease. Radiology 2009; 253(2):317-338.
3. Serruys PW, Morice MC, Kappetein AP, Colombo A, Holmes DR, Mack MJ, Ståhle E, Feldman TE, van den Brand M, Bass EJ, Van Dyck N, Leadley K, Dawkins KD, Mohr FW, for the SYNTAX Investigators. Percutaneous Coronary Intervention versus Coronary-Artery Bypass Grafting for Severe Coronary Artery Disease. N Engl J Med 2009; 360(10):961-972.
4. Sianos G, Morel MA, Kappetein AP, et al. The SYNTAX score: an angiographic tool grading the complexity of CAD. EuroInterv 2005; 1:219-227.
5. Valgimigli M, Serruys PW, Tsuchida K, et al. Cyphering the complexity of coronary artery disease using the syntax score to predict clinical outcome in patients with three-vessel lumen obstruction undergoing percutaneous coronary intervention. Am J Cardiol 2007; 99(8):1072-1081.
6. Van Gaal W, Ponnuthurai F, Selvanayagam J, Testa L, Porto I, Neubauer S, Banning A. The Syntax score predicts peri-procedural myocardial necrosis during percutaneous coronary intervention. Int J Cardiol 2009; 135(1):60-65.
7. Niu J, Kolattukudy PE. Role of MCP-1 in cardiovascular disease: molecular mechanisms and clinical implications. Clin Sci Lond 2009; 117(3):95-109.
8. Park HJ, Chang K, Park CS, Jang SW, Ihm SH, Kim PJ, Baek SH, Seung KB, Choi KB. Coronary collaterals: the role of MCP-1 during the early phase of acute myocardial infarction. Int J Cardiol 2008; 130(3),409-413.
9. Piemonti L, Calori G, Lattuada G, Mercalli A, Ragogna F, Garancini MP, Ruotolo G, Luzi L, Perseghin G. Association between plasma monocyte chemoattractant protein-1 concentration and cardiovascular disease mortality in middle-aged diabetic and nondiabetic individuals. Diabetes Care 2009; 32(11):2105-2110.
10. Visse R, Nagase H. Matrix Metalloproteinases and Tissue Inhibitors of Metalloproteinases. Circ Res 2003; 92:827-839.
11. Brew K, Dinakarpandian D, Nagase H. Tissue inhibitors of metal-loproteinases: evolution, structure and function. Biochim Biophys Acta 2000; 1477:267-283.
12. Woessner JF. The matrix metalloproteinase family. In: Parks WC, Mecham RP, eds. Matrix Metalloproteinases. San Diego, Calif: Academic Press 1998:1-13.
13. Galis ZS, Khatri JJ. Matrix metalloproteinases in vascular remodeling and atherogenesis: the good, the bad, and the ugly. Circ Res 2002; 90:251-262.
14. Creemers EE, Cleutjens JP, Smits JF, Daemen MJ. Matrix metal-loproteinase inhibition after myocardial infarction: a new approach to prevent heart failure? Circ Res 2001; 89:201-210.
15. Spinale FG. Matrix metalloproteinases: regulation and dysregulation in the failing heart. Circ Res 2002; 90:520-530.
16. Siminelakis S, Kotsanti A, Kolaitis N, Niokou D, Vlachou I, Dimakopoulos G, Papadopoulou C. Circulating matrix metal-loproteinase-3 due to myocardial ischemia. The Heart Surgery Forum 2009;12(4):E230-E234.
17. Kelly D, Khan S, Cockerill G, Ng LL, Thompson M, Samani NJ, Squire IB. Circulating stromelysin-1 (MMP-3): a novel predictor of LV dysfunction, remodelling and all-cause mortality after acute myocardial infarction. Eur J Heart Fail 2008; 10(2):133-139.
18. Ohtsuka T, Nishimura K, Kurata A, Ogimoto A, Okayama H, Higaki J. Serum matrix metalloproteinase-3 as a novel marker for risk stratification of patients with nonischemic dilated cardio-myopathy. J Card Fail 2007; 13(9):752-758.
19. Dogan A, Tuzun N, Turker Y, Akcay S, Kaya S, Ozaydin M. Matrix metalloproteinases and inflammatory markers in coronary artery ectasia: their relationship to severity of coronary artery ectasia. Coron Artery Dis 2008;19(8):559-563.
20. Chen QJ, Lu L, Peng WH, Hu J, Yan XX, Wang LJ, Zhang Q, Zhang RY, Shen WF. Polymorphisms of MMP-3 and TIMP-4 genes affect angiographic coronary plaque progression in non-diabetic and type 2 diabetic patients. Clin Chim Acta 2009; 405(1-2):97-103.
21. Antoniades C, Bakogiannis C, Tousoulis D, Antonopoulos AS, Stefanadis C. The CD40/CD40 ligand system: linking inflammation with atherothrombosis. J Am Coll Cardiol 2009; 54 (8):669-677.
22. Chai H, Aghaie K, Zhou W. Soluble CD40 ligand induces human coronary artery smooth muscle cells proliferation and migration. Surgery 2009; 146(1):5-11.
23. Ferroni P, Guadagni F. Soluble CD40L and its role in essential hypertension: diagnostic and therapeutic implications. Cardiovasc Hematol Disord Drug Targets 2008; 8(3):194-202.
24. Penno G, Pucci L, Dell'Omo G, Lucchesi D, Miccoli R, Del Prato S, Solini A, Pedrinelli R. Soluble CD40 ligand levels in essential hypertensive men: evidence of a possible role of insulin resistance. Am J Hypertens 2009; 22(9):1007-1013.
25. Morrow DA, Sabatine MS, Brennan ML, de Lemos JA, Murphy SA, Ruff CT, Rifai N, Cannon CP, Hazen SL. Concurrent evaluation of novel cardiac biomarkers in acute coronary syndrome: myeloperoxidase and soluble CD40 ligand and the risk of recurrent ischaemic events in TACTICS-TIMI 18. Eur Heart J 2008; 29(9):1096-1102.
26. Blanco-Colio LM, Martín-Ventura JL, de Teresa E, Farsang C, Gaw A, Gensini G, Leiter LA, Langer A, Martineau P, Egido J. Atorvastatin decreases elevated soluble CD40L in subjects at high cardiovascular risk. Atorvastatin on inflammatory markers study: a substudy of ACTFAST. Kidney International. Supplement 2008; 111:S60-S63.
27. Weber M, Rabenau B, Stanisch M, Elsaesser A, Mitrovic V, Heeschen C, Hamm C. Influence of sample type and storage conditions on soluble CD40 ligand assessment. Clin Chem 2006; 52:888-891.
28. Halldórsdóttir AM, Stoker J, Porche-Sorbet R, Eby CS. Soluble CD40 Ligand Measurement Inaccuracies Attributable to Specimen Type, Processing Time, and ELISA Method. Clinical Chemistry 2005; 51:1054-1057.
29. Lainez B, Fernandez-Real JM, Romero X, Esplugue E, Cañete JD, Ricart W, Engel P. Identification and characterization of a novel spliced variant that encodes human soluble tumor necrosis factor receptor 2. International Immunology 2004; 16(1):169-177.
30. Plomgaard P, Nielsen AR, Fischer CP, Mortensen OH, Broholm C, Penkowa M, Krogh-Madsen R, Erikstrup C, Lindegaard B, Petersen AMW, Taudorf S, Pedersen BK. Associations between insulin resistance and TNF-α in plasma, skeletal muscle and adipose tissue in humans with and without type 2 diabetes. Diabetologia 2007; 50:2562-2571.
31. Safranow K, Dziedziejko V, Rzeuski R, Czyzycka E, Wojtarowicz A, Bińczak-Kuleta A, Jakubowska K, Olszewska M, Ciechanowicz A, Kornacewicz-Jach Z, Machaliński B, Pawlik A, Chlubek D. Plasma concentrations of TNF-alpha and its soluble receptors sTNFR1 and sTNFR2 in patients with coronary artery disease. Tissue Antigens 2009; 74(5):386-392.
32. Mizia-Stec K, Gasior Z, Zahorska-Markiewicz B, Holecki M, Kumor P. Inflammatory markers in a 2-year follow-up of coronary artery disease. Heart Vessels 2006; 21(5):302-308.
33. Thorand B, Baumert J, Döring A, Herder C, Kolb H, Rathmann W, Giani G, Koenig W. Sex differences in the relation of body composition to markers of inflammation. Atherosclerosis 2006; 184:216-224.
34. Cartier A, Cote M, Lemieux I, Peruss L, Tremblay A, Bouchard C, Despres JP. Sex differences in inflammatory markers: what is the contribution of visceral adiposity? Am J Clin Nutr 2009; 89:1307-1314.
35. Dign EL, Song Y, Malik VS, Liu S. Sex differences of endogenous sex hormones and risk of type 2 diabetes: a systematic review and meta-analysis. JAMA 2006; 295:1288-1299.
36. Wang M, Crisostomo PR, Markel TA, Wang Y, Meldrum DR. Mechanisms of Sex Differences in TNFR2-Mediated Cardioprotection. Circulation 2008; 118(suppl 1):S38-S45.